SOUTHBOROUGH, Mass.–(BUSINESS WIRE) — Veristata global science-based clinical research organization (CRO), today announced the expansion and enhancement of its service capabilities by acquiring SFL (Solutions for life sciences). With its headquarters in Basel, Switzerland, and several European subsidiaries, SFL brings unique capabilities and a highly qualified team to support a growing number of biotech, pharmaceutical and medtech companies.
Led by Founder and CEO Shayesteh Fürst-Ladani, the SFL team has a long history of providing strategic advice and operational support at all stages of product development, with in-house expertise for a wide range of product types. of products, including small molecules, biologics, drugs. combination devices, medical devices, in vitro diagnostics (IVDs) and advanced therapy drugs (ITMs).
The SFL team has extensive experience in a range of therapeutic areas, ranging from specialized expertise in the field of orphan diseases and oncology to future healthcare solutions that combine medicines with artificial intelligence (AI ), devices and diagnostics. SFL is deeply rooted in the EU, UK and Swiss healthcare ecosystem and offers a competitive advantage to US-based companies looking to enter European markets.
“As scientific advances improve our understanding of complex therapeutic challenges, our customers are increasingly looking for a CRO partner with experience in solving the complex challenges of program design, conducting clinical trials and regulatory and marketing approval process,” said Patrick Flanagan, Chief Executive Officer. at Veristat. “We were impressed with Shayesteh and the entire SFL team who have a reputation for delivering high quality, accuracy and value. Adding SFL’s talented team and services to Veristat’s offering will unlock significant potential and strengthen our ability to positively influence scientific progress, regulatory review and launch success for patients with diseases and difficult-to-treat conditions.
With SFL, Veristat is also expanding its quality assurance and pharmacovigilance capabilities in Europe and extending its core service areas to public affairs, market access, supply chain and healthcare compliance. Veristat and SFL share common and extensive skills in regulatory affairs, strategic consulting and medical writing with a complementary geographic focus. Overlaying Veristat’s world-class capabilities in biometrics and clinical trial operations, bringing together the organizations creates a full-service force around clinical research and development to successfully meet the goals of sponsors and customers with a interest in the European region.
“The acquisition of SFL adds European, UK and Swiss political experience in the pharmaceutical sector as well as in the field of medical technology,” commented Montse Barceló Riera, MD, Vice President Europe of Veristat. “We are now able to further support the health and wellbeing of Europeans by advocating for access to high quality medical treatment.”
“I am thrilled to have the opportunity to unite two experienced and deeply committed teams with a passion for quality and bold thinking,” said Shayesteh Fürst-Ladani. “We are now equipped with unparalleled capabilities to deliver even more value to sponsors and customers. I share Veristat’s unwavering commitment to scientific integrity, exceptional performance, and enduring customer relationships, and I’m excited to embark on a new journey of growth together.
Since the company was founded 27 years ago, Veristat has worked with hundreds of biopharmaceutical customers around the world to prepare more than 140 marketing applications. Veristat’s bold thinking, focus and vast experience in developing complex drugs for rare and ultra-rare diseases has had a significant impact on the approval of 12% of new drugs from the Food and Drug Administration (FDA) of the United States in 2021. The company will continue to offer a flexible partner engagement model that provides the right scientific expertise when needed throughout the development journey to avoid project delays, missed milestones or failures of deliverables.
SFL is a leading consultancy based in Switzerland with subsidiaries in Austria, Germany and the United Kingdom, providing integrated solutions to pharmaceutical, biotechnology and medical companies for global and local activities, from test bench to market. SFL’s expertise and in-house services reflect key functions throughout the lifecycle of a pharma or medtech product: regulatory affairs, quality assurance, pharmacovigilance, medical writing, market access, public affairs, supply chain and healthcare compliance.
SFL supports a variety of clients and sponsors ranging from big pharma to emerging biotechs to leading diagnostics and medical device manufacturers. SFL can act as MA Applicant Application (MAA) and as a Marketing Authorization Holder (MAH) in Switzerland, the EU and the UK, and make submissions to health authorities around the world, including the PMDA of Japan and Health Canada through long-term local partners.
Veristat, a science-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies from clinical development to regulatory approval. With over 27 years of experience planning and executing clinical trials, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities over the past 10 years.
Veristat’s focus on new drug development has successfully managed the unknowns that arise in complex therapeutic areas, such as rare/ultra-rare diseases, advanced therapies, oncology and drug trials. Infectious diseases. We apply this knowledge base every day to solve the challenges of any clinical program, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts from around the world who understand the intricacies of therapeutic development, enabling sponsors to successfully prolong and save lives.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220307005044/en/